CVL 936
Alternative Names: CVL-936Latest Information Update: 05 Aug 2024
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics
- Class Drug withdrawal therapies
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Substance-related disorders
Most Recent Events
- 01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie
- 01 Mar 2022 Discontinued - Phase-I for Substance-related disorders (In volunteers) in USA, in March 2022 (PO)
- 31 Dec 2021 Cerevel Therapeutics has patent protection for CVL 936 in the US, foreign jurisdictions including Australia, Canada, China, Japan, Russia and various member states of the European Patent Office prior to December 2021